Alzheimer’s disease (AD) is a neurodegenerative disorder, characterized by degeneration of neurons leading to memory loss, deterioration in cognitive function and behavior. Despite intensive research of several decades treatment of AD is still a major challenge. Riluzole is known to be neuro-protector and regulates the function of glutamatergic neurons by reducing glutamate release and helping astroglial uptake. In this study, we have evaluated the impacts of Riluzole on the neuronal activity in the AβPP-PS1 mouse model of the AD by 1H-[13C]-NMR spectroscopy together with infusion of [1,6-13C2]glucose. The finding of improved neurometabolism in AD mice suggests riluzole improved cognitive function in Alzheimer's disease.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords